Evidence map›Paper›PMID 36878319›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

A mannosylated polymer with endosomal release properties for peptide antigen delivery.

Kefan Song, Dinh Chuong Nguyen, Tran Luu, Omeed Yazdani, Debashish Roy, Patrick S Stayton, Suzie H Pun

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kefan SongDepartment of Bioengineering, University of Washington, USA.
Dinh Chuong NguyenMolecular Engineering & Sciences Institute, University of Washington, USA.
Tran LuuDepartment of Bioengineering, University of Washington, USA.
Omeed YazdaniDepartment of Bioengineering, University of Washington, USA.
Debashish RoyDepartment of Bioengineering, University of Washington, USA.
Patrick S StaytonDepartment of Bioengineering, University of Washington, USA; Molecular Engineering & Sciences Institute, University of Washington, USA. Electronic address: stayton@uw.edu.
Suzie H PunDepartment of Bioengineering, University of Washington, USA; Molecular Engineering & Sciences Institute, University of Washington, USA. Electronic address: spun@uw.edu.
University of Washington · US

Funding

An integrated polymeric carrier for subunit cancer vaccinesR01CA257563 · NCI · UNIVERSITY OF WASHINGTON · PI PUN, SUZIE H., STAYTON, PATRICK S. · 2021 to 2025
$2.4M
Leica SP8 WWL Confocal MicroscopeS10OD016240 · OD · UNIVERSITY OF WASHINGTON · PI CATTERALL, WILLIAM A · 2014 to 2014
$581k
NCI NIH HHS R01 CA257563NIH HHS S10 OD016240
6 · The paper itself

Abstract

Peptide cancer vaccines have had limited clinical success despite their safety, characterization and production advantages. We hypothesize that the poor immunogenicity of peptides can be surmounted by delivery vehicles that overcome the systemic, cellular and intracellular drug delivery barriers faced by peptides. Here, we introduce Man-VIPER, a self-assembling (40-50 nm micelles), pH-sensitive, mannosylated polymeric peptide delivery platform that targets dendritic cells in the lymph nodes, encapsulates peptide antigens at physiological pH, and facilitates endosomal release of antigens at acidic endosomal pH through a conjugated membranolytic peptide melittin. We used d-melittin to improve the safety profile of the formulation without compromising the lytic properties. We evaluated polymers with both releasable (Man-VIPER-R) or non-releasable (Man-VIPER-NR) d-melittin. Both Man-VIPER polymers exhibited superior endosomolysis and antigen cross-presentation compared to non-membranolytic d-melittin-free analogues (Man-AP) in vitro. In vivo, Man-VIPER polymers demonstrated an adjuvanting effect, induced the proliferation of antigen-specific cytotoxic T cells and helper T cells compared to free peptides and Man-AP. Remarkably, antigen delivery with Man-VIPER-NR generated significantly more antigen-specific cytotoxic T cells than Man-VIPER-R in vivo. As our candidate for a therapeutic vaccine, Man-VIPER-NR exerted superior efficacy in a B16F10-OVA tumor model. These results highlight Man-VIPER-NR as a safe and powerful peptide cancer vaccine platform for cancer immunotherapy.

Indexed as

Cancer VaccinesNeoplasmsAntigen PresentationAntigensDendritic CellsDrug Delivery SystemsHumansPeptidesPolymersAntigensCancer VaccinesPeptidesPolymersCancer immunotherapyCancer vaccineCross-presentationDrug deliveryEndosomal escapeMicellesPolymer-peptide conjugates

Identifiers

PMID36878319
PMCPMC10693254
OpenAlexW4323348852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.